A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma (NCT02979522)
An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Colorado — Aurora, Colorado
Age range: 5 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Children's Hospital Colorado — Aurora, Colorado
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Hospital Sao Rafael S/A — Salvador, Estado de Bahia
- Jardim das Americas — Paranã,
- INCA - Instituto Nacional de Cancer — Rio de Janeiro,
- GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer — São Paulo,
- ICr - Instituto da Crianca - HCFMUSP — São Paulo,
- Hospital Santa Marcelina — São Paulo,
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer — Florence,
- Fondazione IRCCS Policlinico San Matteo — Pavia,
- Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia — Roma,
- Azienda Ospedaliera Citta della Salute e della Scienza di Torino — Torino,
- NHO Nagoya Medical Center — Nagoya, Aichi-ken
- St. Marianna University School of Medicine Hospital — Kawasaki-shi, Kanagawa
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hodgkin Disease
- Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) — Houston, Texas
- Administration of T Lymphocytes for Prevention of Relapse of Lymphomas — Chapel Hill, North Carolina
- Tissue Collection for Studies of Lymph Cancer — Bethesda, Maryland
- Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies — Milwaukee, Wisconsin
Explore by condition: All Hodgkin Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.